Safety and Efficacy of CDCA in CTX Chenodeoxycholic Acid (CDCA) in Patients Affected by Cerebrotendinous Xanthomatosis (CTX)
Overview
Retrospective study of CTX patients to investigate the safety and clinical efficacy of Chenodeoxycholic Acid
Full Title of Study: “Retrospective Cohort Study to Investigate the Safety and Efficacy of Chenodeoxycholic Acid (CDCA) in Patients Affected by Cerebrotendinous Xanthomatosis (CTX)”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Retrospective
- Study Primary Completion Date: June 3, 2015
Interventions
- Drug: Chenodeoxycholic Acid
- Bile acid
Clinical Trial Outcome Measures
Primary Measures
- Serum Cholestanol Levels
- Time Frame: 34 years
Participating in This Clinical Trial
Inclusion Criteria
Diagnosis of CTX Received treatment with CDCA Age between 2 and 75 years Having at least one cholestanol level and/or urinary bile alcohol level no more than 3 months prior to treatment with CDCA and one cholestanol level and/or urinary bile alcohol level post-treatment within 2 years from the beginning of therapy with CDCA Exclusion Criteria:
-
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: N/A
Investigator Details
- Lead Sponsor
- Leadiant Biosciences Ltd.
- Provider of Information About this Clinical Study
- Sponsor
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.